Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer
Jiao Sun(Tianjin Medical University Cancer Institute and Hospital), Hongfeng Yuan(Tianjin Medical University Cancer Institute and Hospital), Linlin Sun(Tianjin Medical University Cancer Institute and Hospital), Lina Zhao(Tianjin Medical University Cancer Institute and Hospital), Yufei Wang(Tianjin Medical University Cancer Institute and Hospital), Chunyu Hou(Tianjin Medical University Cancer Institute and Hospital), Huihui Zhang(Tianjin Medical University Cancer Institute and Hospital), Pan Lv(Tianjin Medical University Cancer Institute and Hospital), Guang Yang(Tianjin Medical University Cancer Institute and Hospital), Ningning Zhang(Tianjin Medical University Cancer Institute and Hospital), Wei Lü(Tianjin Medical University Cancer Institute and Hospital), Xiaodong Zhang(Tianjin Medical University Cancer Institute and Hospital)
Cited by 7Open Access
Abstract
T-cell-mediated antitumor immunity. Notably, combining the PRMT5 methyltransferase inhibitor GSK591 with PD-L1 blockade efficiently inhibited liver cancer growth and improved overall survival in mice. Collectively, our findings reveal the immunosuppressive role and mechanism of PRMT5 in liver cancer and highlight that targeting PRMT5 could boost checkpoint immunotherapy efficacy.
Related Papers
No related papers found
Powered by citation graph analysis